In-house development:

IPI develops sterile injectable pharmaceutical products in its state of the art R&D laboratories, located in Monmouth Junction, New Jersey.

     • The formulations include solutions, suspensions, lyophilized as well as emulsion products.

     • Presentations include ampoules, vials and pre-filled syringes.

The scope of R&D activities include analytical methods development and validation for API as well as finished drug product, and product development activities, including pre-formulation, formulation and manufacturing process development and optimization. All development activities are designed keeping in perspective the challenges during scale-up into cGMP manufacturing environment.

Products in IPI’s development pipeline include small molecules, polypeptides, carbohydrates as well as phospholipid based products, covering various therapeutic categories, primarily including oncology and cardiovascular.

Collaborative development:

IPI develops solid oral dosage form products through collaboration with its development and manufacturing partners. IPI’s solid oral product pipeline includes sustained release tablets and capsules, utilizing technologies such as press-coat, pelletization and related technologies.